This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The purpose of this study is to test the hypothesis that omalizumab (Xolair, a humanized monoclonal antibody against IgE) will decrease the influx of neutrophils (PMNs) to the airway after ozone challenge. We also hypothesize that omalizumab will reduce the effects of ozone on lung function and airway reactivity, and we will examine these as secondary hypotheses. This study will be conducted as a placebo-controlled, double-blinded, two arm )placebo and omalizumab) study. Mild, mite sensitive asthmatics will be recruited into the study and randomized to receive either omalizumab or placebo for 13 weeks. At week 13 they will undergo either the clean air or O(3) challenge and in week 16 they will undergo the exposure not done on week 13 (all subjects will get both exposures but order is randomized). The post-0(3) responses between the placebo and omalizumab will be compared after each endpoint has been adjusted for its paired post air control. Subjects for this study will be otherwise healthy allergic mild asthmatic (as defined by NHLBI guidelines), 18-50 year old males and females with a <0.5 pack year history of tobacco use. The recruitment goal is 40 subjects.
Showing the most recent 10 out of 782 publications